These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 28089149)
41. Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes undergoing left main percutaneous coronary intervention. Jaberg L; Toggweiler S; Puck M; Frank M; Rufibach K; Lüscher TF; Corti R Circ J; 2011; 75(11):2648-53. PubMed ID: 21891968 [TBL] [Abstract][Full Text] [Related]
42. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. Damman P; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ; J Am Coll Cardiol; 2010 Mar; 55(9):858-64. PubMed ID: 20045278 [TBL] [Abstract][Full Text] [Related]
43. A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. Dong M; Liao JK; Yan B; Li R; Zhang M; Yu CM Int J Cardiol; 2013 Sep; 167(6):2813-9. PubMed ID: 22921817 [TBL] [Abstract][Full Text] [Related]
44. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756 [TBL] [Abstract][Full Text] [Related]
45. N-terminal pro-brain natriuretic peptide improves the C-ACS risk score prediction of clinical outcomes in patients with ST-elevation myocardial infarction. He PC; Duan CY; Liu YH; Wei XB; Lin SG BMC Cardiovasc Disord; 2016 Dec; 16(1):255. PubMed ID: 27955618 [TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. Melloni C; James SK; White JA; Giugliano RP; Harrington RA; Huber K; Tricoci P; Armstrong PW; Van de Werf F; Montalescot G; Califf RM; Newby LK Am Heart J; 2011 Nov; 162(5):884-892.e1. PubMed ID: 22093205 [TBL] [Abstract][Full Text] [Related]
47. Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. Fabris E; Kilic S; Schellings DAAM; Ten Berg JM; Kennedy MW; van Houwelingen KG; Giannitsis E; Kolkman E; Ottervanger JP; Hamm C; Van't Hof AWJ Heart; 2017 Oct; 103(19):1515-1520. PubMed ID: 28679686 [TBL] [Abstract][Full Text] [Related]
48. Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Halim SA; Clare RM; Newby LK; Lokhnygina Y; Schweiger MJ; Hof AW; Hochman JS; James SK; White HD; Widimsky P; Betriu A; Bode C; Giugliano RP; Harrington RA; Zeymer U Int J Cardiol; 2016 Jan; 203():708-13. PubMed ID: 26587725 [TBL] [Abstract][Full Text] [Related]
49. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457 [TBL] [Abstract][Full Text] [Related]
50. NT-proBNP levels in patients with non-ST-segment elevation acute coronary syndrome. Castro LR; Alencar MC; Barbosa MM; Nunes Mdo C; Cardoso JR; Ribeiro AL Arq Bras Cardiol; 2011 Dec; 97(6):456-61. PubMed ID: 22030563 [TBL] [Abstract][Full Text] [Related]
51. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS; JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608 [TBL] [Abstract][Full Text] [Related]
52. Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP. Squire I; Quinn P; Narayan H; Khan S; Dhillon O; Ng K; Kelly D; Davies J; Ng L Heart; 2010 Jun; 96(11):831-7. PubMed ID: 20478862 [TBL] [Abstract][Full Text] [Related]
53. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention. Kwon TG; Bae JH; Jeong MH; Kim YJ; Hur SH; Seong IW; Cho MC; Seung KB; Jang YS; Park SJ; Int J Cardiol; 2009 Apr; 133(2):173-8. PubMed ID: 18281115 [TBL] [Abstract][Full Text] [Related]
54. Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. Gravning J; Smedsrud MK; Omland T; Eek C; Skulstad H; Aaberge L; Bendz B; Kjekshus J; Mørkrid L; Edvardsen T Am Heart J; 2013 May; 165(5):716-24. PubMed ID: 23622908 [TBL] [Abstract][Full Text] [Related]
55. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Windhausen F; Hirsch A; Sanders GT; Cornel J; Fischer J; van Straalen JP; Tijssen JG; Verheugt FW; de Winter RJ; Am Heart J; 2007 Apr; 153(4):485-92. PubMed ID: 17383283 [TBL] [Abstract][Full Text] [Related]
56. The Prognostic Value of Serum Levels of Heart-Type Fatty Acid Binding Protein and High Sensitivity C-Reactive Protein in Patients With Increased Levels of Amino-Terminal Pro-B Type Natriuretic Peptide. Jeong JH; Seo YH; Ahn JY; Kim KH; Seo JY; Kim MJ; Lee HT; Park PW Ann Lab Med; 2016 Sep; 36(5):420-6. PubMed ID: 27374706 [TBL] [Abstract][Full Text] [Related]
57. Prognostic value of N-terminal-pro-brain natriuretic peptide measurements in patients with acute coronary syndromes. Ranjith N; Pegoraro RJ; Naidoo DP; Esterhuizen TM Cardiovasc J S Afr; 2006; 17(2):60-6. PubMed ID: 16733598 [TBL] [Abstract][Full Text] [Related]
59. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. Yu J; Oh PC; Kim M; Moon J; Park YM; Lee K; Suh SY; Han SH; Byun K; Ahn T; Kang WC PLoS One; 2017; 12(8):e0182829. PubMed ID: 28796845 [TBL] [Abstract][Full Text] [Related]
60. Prediction of clinical outcome in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) using the TIMI risk score extended by N-terminal pro-brain natriuretic peptide levels. Jarai R; Iordanova N; Jarai R; Jarai F; Raffetseder A; Woloszczuk W; Gyöngyösi M; Geyer G; Wojta J; Huber K Wien Klin Wochenschr; 2007; 119(21-22):626-32. PubMed ID: 18043882 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]